Investor Presentation H1 2023
16
Investor presentation
First six months of 2023
R&D milestones
Diabetes care
Obesity care
Novo NordiskⓇ
Clinical milestones¹
Regulatory milestones¹
Project
Q2 2023
Q3 2023
Oral semaglutide (25/50mg)
Cagrisema T2D
US submission
Phase 3 initiation
Q4 2023
EU submission
OW GLP-1/GIP
SemaDapa
Phase 2 initiation
Oral semaglutide (50 mg)
Phase 3 results
✓ Phase 1 results
US submission
EU submission
✓ Phase 3 results
SELECT CVOT
US/EU Submission
STEP HFPEF
PYY 1875
✓ Phase 3 results
✓ Phase 1/2 results
Phase 3 results (T2D)
Rare disease
Other serious chronic diseases
Oral Amycretin
Sogroya® (Somapacitan)
Ziltivekimab (HFPEF)
✓ EU/JP approval (GHD)
✓ Phase 3 initiation
Phase 1 results
1Expected to be published in the given quarter or in the subsequent quarterly company announcement
CVOT: Cardiovascular Outcomes Trial; EU: European Union; GHD: Growth Hormone Deficiency; GIP: Gastric inhibitory polypeptide; GLP-1: Glucagon Like Peptide 1; HFPEF: Heart failure with preserved ejection fraction; JP: Japan; OW: once weekly; PYY: Peptide YY;
T2D: Type 2 Diabetes Mellitus; US: United StatesView entire presentation